The forum will feature 20-minute presentations (including Q&A) from a curated selection of exciting start-up companies, all carefully selected through our screening processes. You will also see updated presentations from past presenting companies.
Targeted Oncolytic Peptides (TOPs) are the next generation of targeted cancer therapy. TOPs conjugates are less expensive, less complex and provide a more specific way of killing cancer cells without harming healthy cells all while recruiting the immune system to join the fight.
Mind Pharma, a Yale IP–backed biotech, develops next-gen psychedelic treatments for psychiatric and CNS disorders. Focus: depression, migraine, and cluster headaches. Its short-acting model improves scalability, offering less frequent dosing than J&J’s Esketamine. Proof of concept studies completed in 48 participants and more than 100 patients underway at Yale.
Today, doctors often have to wait until the tumor grows large enough to become detectable because current clinical tools cannot detect microscopic cancers in real time. At this stage, it is often too late to cure. SCORPIDO PHOTONICS converts the founder’s breakthrough discovery into a device that instantly and safely detects and treats even microscopic cancers, otherwise undetectable, in patients during the standard biopsy or surgery. This enables earlier treatment, and saves many lives and cancer care costs.